|
|
|
|
| LEADER |
03899nam a22004935i 4500 |
| 001 |
978-1-59745-274-8 |
| 003 |
DE-He213 |
| 005 |
20210616213403.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2008 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781597452748
|9 978-1-59745-274-8
|
| 024 |
7 |
|
|a 10.1007/978-1-59745-274-8
|2 doi
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 072 |
|
7 |
|a MJCL
|2 thema
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Checkpoint Responses in Cancer Therapy
|h [electronic resource] /
|c edited by Wei Dai.
|
| 250 |
|
|
|a 1st ed. 2008.
|
| 264 |
|
1 |
|a Totowa, NJ :
|b Humana Press :
|b Imprint: Humana,
|c 2008.
|
| 300 |
|
|
|a XIV, 314 p. 33 illus., 3 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Cancer Drug Discovery and Development,
|x 2196-9906
|
| 505 |
0 |
|
|a RB-Pathway -- Targeting the p53/MDM2 Pathway for Cancer Therapy -- DNA Topoisomerases as Targets for the Chemotherapeutic Treatment of Cancer -- Targeting ATM/ATR in the DNA Damage Checkpoint -- Compounds that Abrogate the G2 Checkpoint -- CDK Inhibitors as Anticancer Agents -- CHFR as a Potential Anticancer Target -- Antimicrotubule Agents -- Kinesin Motor Inhibitors as Effective Anticancer Drugs -- Targeting the Spindle Checkpoint in Cancer Chemotherapy -- Antiproliferation Inhibitors Targeting Aurora Kinases -- Plks as Novel Targets for Cancer Drug Design -- Do Histone Deacetylase Inhibitors Target Cell Cycle Checkpoints that Monitor Heterochromatin Structure?.
|
| 520 |
|
|
|a Extensive research has uncovered a set of molecular surveillance mechanisms – commonly called "checkpoints" – which tightly monitor cell-cycle processes. Today’s anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now promises to uncover a new generation of anticancer drugs with improved therapeutic indices based on their ability to target emerging checkpoint components. Checkpoint Responses in Cancer Therapy summarizes the advances made over the past 20 years, identifying components of cell-cycle checkpoints and their molecular regulation during checkpoint activation and validating the use of checkpoint proteins as targets for the development of anticancer drugs. This book’s distinguished panel of authors takes a close look at topics ranging from the major molecular players affecting DNA synthesis and the response to DNA damage to advances made in the identification of chemical compounds capable of inhibiting individual mitotic kinases. Illuminating and authoritative, Checkpoint Responses in Cancer Therapy offers a critical summary of findings for researchers in the pharmaceutical and biotechnology industries and a valuable resource for academic scientists in cancer research and the study of cell-cycle regulation, signal transduction and apoptosis.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
1 |
4 |
|a Cancer Research.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/B11001
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/B21007
|
| 700 |
1 |
|
|a Dai, Wei.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer Nature eBook
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9781603277976
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9781617378478
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9781588299307
|
| 830 |
|
0 |
|a Cancer Drug Discovery and Development,
|x 2196-9906
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-59745-274-8
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 912 |
|
|
|a ZDB-2-SXB
|
| 950 |
|
|
|a Biomedical and Life Sciences (SpringerNature-11642)
|
| 950 |
|
|
|a Biomedical and Life Sciences (R0) (SpringerNature-43708)
|
